To include your compound in the COVID-19 Resource Center, submit it here.

No safety signals with Zafgen's ZGN-1061 in second cohort of diabetes trial

Zafgen Inc. (NASDAQ:ZFGN) said the 1.8 mg subcutaneous dose of ZGN-1061 met primary and secondary endpoints in a second dose cohort from a Phase II trial to

Read the full 274 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers